Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Clinical implications of multiple glioblastomas: An analysis of prognostic factors and survival to distinguish from their single counterparts.

Shieh LT, Guo HR, Chang YK, Lu NM, Ho SY.

J Formos Med Assoc. 2019 Sep 10. pii: S0929-6646(19)30251-7. doi: 10.1016/j.jfma.2019.08.024. [Epub ahead of print]

2.

Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.

Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y.

J Neurooncol. 2016 Apr;127(2):355-62. doi: 10.1007/s11060-015-2046-0. Epub 2016 Jan 2.

PMID:
26725096
3.

Treatment and survival of patients harboring histological variants of glioblastoma.

Ortega A, Nuño M, Walia S, Mukherjee D, Black KL, Patil CG.

J Clin Neurosci. 2014 Oct;21(10):1709-13. doi: 10.1016/j.jocn.2014.05.003. Epub 2014 Jun 26.

PMID:
24980627
4.

Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.

Damodaran O, van Heerden J, Nowak AK, Bynevelt M, McDonald K, Marsh J, Lee G.

J Clin Neurosci. 2014 Mar;21(3):478-81. doi: 10.1016/j.jocn.2013.07.042. Epub 2013 Oct 30.

PMID:
24332268
5.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
6.

Pathological and clinical features of cystic and noncystic glioblastomas.

Utsuki S, Oka H, Suzuki S, Shimizu S, Tanizaki Y, Kondo K, Tanaka S, Kawano N, Fujii K.

Brain Tumor Pathol. 2006 Apr;23(1):29-34.

PMID:
18095116
7.

Outcome and prognostic factors in adult cerebellar glioblastoma.

Babu R, Sharma R, Karikari IO, Owens TR, Friedman AH, Adamson C.

J Clin Neurosci. 2013 Aug;20(8):1117-21. doi: 10.1016/j.jocn.2012.12.006. Epub 2013 May 22.

PMID:
23706183
8.

The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population.

Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Barón AE, Yeh N, Gaspar LE, Liu AK, Ney DE, Damek DM, Lillehei KO, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):894-902. doi: 10.1016/j.ijrobp.2014.07.046. Epub 2014 Oct 18.

PMID:
25585784
9.

Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.

Han SJ, Yang I, Otero JJ, Ahn BJ, Tihan T, McDermott MW, Berger MS, Chang SM, Parsa AT.

J Neurosurg. 2010 May;112(5):990-6. doi: 10.3171/2009.9.JNS09931.

PMID:
19817543
10.

Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.

Thomas JG, Rao G, Kew Y, Prabhu SS.

Neurosurg Focus. 2016 Oct;41(4):E12.

PMID:
27690657
11.

Gliosarcoma: a clinical and radiological analysis of 48 cases.

Yi X, Cao H, Tang H, Gong G, Hu Z, Liao W, Sun L, Chen BT, Li X.

Eur Radiol. 2019 Jan;29(1):429-438. doi: 10.1007/s00330-018-5398-y. Epub 2018 Jun 12.

PMID:
29948068
12.

Cystic glioblastoma multiforme: survival outcomes in 22 cases.

Maldaun MV, Suki D, Lang FF, Prabhu S, Shi W, Fuller GN, Wildrick DM, Sawaya R.

J Neurosurg. 2004 Jan;100(1):61-7.

PMID:
14743913
13.

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome.

Kozak KR, Mahadevan A, Moody JS.

Neuro Oncol. 2009 Apr;11(2):183-91. doi: 10.1215/15228517-2008-076. Epub 2008 Sep 9.

14.

Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis.

Pallud J, Dezamis E, Audureau E, Devaux B, Souillard-Scemama R, Sanai N, Page P, Beuvon F, Koziak M, Oppenheim C, Dhermain F, Schlienger M, Meder JF, Roux FX, Varlet P.

J Neurosurg. 2012 Sep;117(3):476-85. doi: 10.3171/2012.5.JNS111670. Epub 2012 Jun 22.

PMID:
22725988
15.

Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.

Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G Jr.

J Neurosurg. 1998 Sep;89(3):425-30.

PMID:
9724117
16.

Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.

Ortega A, Sarmiento JM, Ly D, Nuño M, Mukherjee D, Black KL, Patil CG.

J Clin Neurosci. 2016 Feb;24:105-11. doi: 10.1016/j.jocn.2015.05.047. Epub 2015 Dec 5.

PMID:
26671314
17.

Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.

Shwetha SD, Shastry AH, Arivazhagan A, Santosh V.

Pathol Res Pract. 2016 Jan;212(1):17-23. doi: 10.1016/j.prp.2015.11.002. Epub 2015 Nov 14.

PMID:
26616112
18.

Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.

Saito T, Sugiyama K, Takeshima Y, Amatya VJ, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K.

J Neurosurg. 2018 Mar;128(3):679-684. doi: 10.3171/2016.11.JNS162326. Epub 2017 Apr 21.

PMID:
28430038
19.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
20.

Radiotherapy plus concomitant temozolomide in primary gliosarcoma.

Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J.

J Neurooncol. 2016 Jun;128(2):341-8. doi: 10.1007/s11060-016-2117-x. Epub 2016 Mar 30.

PMID:
27025857

Supplemental Content

Support Center